184 related articles for article (PubMed ID: 22571585)
1. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
Alsharqi A; Parslew R; Dever B; Arslanian V
Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
[No Abstract] [Full Text] [Related]
2. Viewpoint on handling anti-TNF failure in psoriasis.
Bracke S; Lambert J
Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
[TBL] [Abstract][Full Text] [Related]
3. Advertisements for TNF Inhibitors.
Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
[No Abstract] [Full Text] [Related]
4. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
5. [Long-term psoriasis treatment].
Jullien D; Battistella M
Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
[No Abstract] [Full Text] [Related]
6. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
8. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
Bachelez H; Battistella M
Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
[No Abstract] [Full Text] [Related]
9. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
11. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
12. TNF-alpha inhibitors in dermatology.
Cordoro KM; Feldman SR
Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
[TBL] [Abstract][Full Text] [Related]
13. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
Braun J
Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
[No Abstract] [Full Text] [Related]
14. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
[TBL] [Abstract][Full Text] [Related]
15. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
Ozmen I; Erbil AH; Koc E; Tunca M
J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
[No Abstract] [Full Text] [Related]
16. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
[TBL] [Abstract][Full Text] [Related]
17. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
19. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
Egnatios G; Warthan MM; Pariser R; Hood AF
J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
[No Abstract] [Full Text] [Related]
20. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
[Next] [New Search]